Longitude - instructions for use, analogs, testimonials and release forms (candles 3000 IU, injections in ampoules for injection 1500 IU and 3000 IU) of a drug for the treatment of adhesions, contractures and scars in adults, children and in pregnancy

In this article, you can read the instructions for using the drug Longitude. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Longidase in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Longidase in the presence of existing structural analogues. Use to treat adhesions, contractures and scars in adults, children, as well as during pregnancy and lactation.

Longitude - a drug with proteolytic activity.Longidase is a conjugate of hyaluronidase with a derivative of the N-oxide of poly-1,4-ethylene-piperazine. It has enzymatic proteolytic (hyaluronidase) activity of prolonged action, immunomodulating, chelating, antioxidant and anti-inflammatory action.

Prolongation of the drug is due to covalent binding of the enzyme with a physiologically active high-molecular carrier (activated derivative of N-oxide poly-1,4-ethylene piperazine), which has its own pharmacological activity: it has an immunomodulating, detoxifying and antioxidant effect.

The presence of a covalent bond significantly increases the resistance of the enzyme to denaturing effects and the effect of inhibitors. The enzymatic activity of Longidase persists with heating to 37 ° C for 20 days, while native hyaluronidase under the same conditions loses its activity during the day.

The covalent bond provides simultaneous local presence of a hydrolytic enzyme and a carrier capable of binding releasing enzyme inhibitors and stimulators of collagen synthesis (iron ions, copper ions, heparin).Thanks to these properties, Longidase has not only the ability to depolymerize the matrix of connective tissue in fibro-granulomatous formations, but also to inhibit the reverse regulatory reaction directed at the synthesis of connective tissue components.

The specific substrate of testicular hyaluronidase is glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate), which form the basis of the connective tissue matrix. As a result of depolymerization (disruption of the bond between C1 acetyl glycosamine and C4 glucuronic or induronic acids) under the influence of hyaluronidase, glycosaminoglycans lose their basic properties (viscosity, ability to bind water, metal ions). It is also difficult to form collagen proteins in fibers, increase the permeability of tissue barriers, facilitate movement of fluid in the intercellular space, and increase the elasticity of connective tissue. The effect of the drug leads to a reduction in swelling of the tissue, flattening of the scars, an increase in the volume of movement of the joints, a reduction in contractures and adhesions and prevention of their formation.

The drug reduces the manifestation of the acute phase of the inflammatory process, regulates (increases or decreases depending on the baseline level) the synthesis of inflammatory mediators (interleukin-1 and tumor necrosis factor), increases resistance to infection and a humoral immune response.

Longidase does not have mitogenic, polyclonal activity, does not have mutagenic, embryotoxic, teratogenic and carcinogenic effects.

Composition

Longidase with hyaluronidase activity + auxiliary substances.

Pharmacokinetics

With parenteral administration, the drug is rapidly absorbed into the systemic bloodstream from the injection site. Characterized by a high rate of distribution, the half-distribution period is about 30 minutes. Penetrates into all organs and tissues (including through the blood-brain barrier (GEB) and the blood-ophthalmic barrier). Do not cumulate. In the body, hyaluronidase undergoes hydrolysis and is excreted mainly by the kidneys. The carrier is metabolized to low-molecular compounds (oligomers), which are excreted by the kidneys.

With rectal administration, the drug is rapidly absorbed into the systemic circulation. Bioavailability of rectal suppositories of Longidazum is not less than 70%.The drug penetrates into all organs and tissues (including through the BBB and hemato-ophthalmic barrier). Do not cumulate in tissues. It is excreted mainly by the kidneys.

Indications

Adults and adolescents over 12 years of age in the form of monotherapy and as part of complex therapy of diseases accompanied by hyperplasia of connective tissue (including and against the background of the inflammatory process).

In urology:

• chronic prostatitis;
• interstitial cystitis;
• strictures of the urethra and ureters;
• Peyronie's disease;
• the initial stage of benign prostatic hyperplasia;
• prevention of scar formation and strictures after surgery on the urethra, bladder, ureters.

In gynecology:

• prevention and treatment of adhesive process in the small pelvis in chronic inflammatory diseases of internal genital organs;
• prevention and treatment of adhesive process in the small pelvis after gynecological manipulations (including artificial abortions, previously performed surgical interventions on the pelvic organs);
• intrauterine synechia;
• tubal peritoneal infertility;
• chronic endomyometritis.

In dermatovenerology:

• limited scleroderma;
• prevention of fibrotic complications of sexually transmitted infections.

In surgery:

• prevention and treatment of adhesions after surgical interventions on the abdominal organs;
• adhesive disease;
• keloid, hypertrophic, scars after pyoderma, trauma, burns, surgeries;
• joint contractures, arthritis, hematomas;
• long-lasting non-healing wounds.

In pulmonology and phthisiology:

• pneumofibrosis;
• siderosis;
• tuberculosis (cavernous-fibrous, infiltrative, tuberculoma);
• interstitial pneumonia;
• fibrosing alveolitis;
• pleurisy.

To increase the bioavailability of antibiotic therapy in urology, gynecology, dermatovenereology, surgery and pulmonology.

Forms of release

Candles for vaginal or rectal use 3000 IU.

Lyophilizate for the preparation of solution for intramuscular and subcutaneous injection (injections in ampoules for injection) 1500 IU and 3000 IU.

Instructions for use and how to use them

Ampoules

The dosage regimen and the mode of administration are set individually, depending on the clinical course and severity of the disease, the age of the patient.

Longitudase is administered subcutaneously (near the lesion site or under scar tissue) or by intramuscular injection at a dose of 3000 IU with a course of 5 to 15 injections (depending on the severity of the disease) with an interval between administrations of 3 to 10 days.

If necessary, recommending a second course in 2-3 months.

In diseases accompanied by a severe chronic productive process in the connective tissue, it is recommended, after a standard course, Longidaza maintenance therapy in a dose of 3000 IU with interruptions between 10-14 days.

To increase the bioavailability of drugs Longinazu is administered at a dose of 1500 IU.

Recommended treatment regimens

1. In pulmonology, urology, gynecology, dermatovenereology

With diseases of the respiratory system, the drug is given in / m in a dose of 3000 IU once every 3-5 days with a total course of 10 injections. Further long-term therapy (from 3-4 months to 1 year) at a dose of 3000 IU is possible every 10-14 days.

With diseases of the pelvic organs, the drug is given in / m in a dose of 3000 IU once every 3-5 days with a total course of 5 to 15 injections.

With limited scleroderma of various forms and localization, the drug is administered in / m at a dose of 3000-4500 IU every 3 days with a course of 5-15 injections.The dose and duration of the course of treatment are selected individually depending on the clinical course, stage, localization of the disease and the individual characteristics of the patient.

2. In orthopedics, surgery, cosmetology

With keloid, hypertrophic scars after pyoderma, burns, and operations, the drug is injected into the rumen at a dose of 3000 IU in 1-2 ml 1-2 times a week with a course of 5-10 injections and / or IM once or every 3-5 days with a common course up to 10 injections.

With long-term non-healing wounds, the drug is administered intramuscularly at a dose of 1500-3000 IU every 5 days with a course of 5-7 injections.

With joint contractures, arthritis, hematomas, Longidaz is prescribed an I / m dose of 3000 IU 1-2 times a week, with a course of 7 to 15 injections.

In the case of adhesive disease, the drug is injected / m once every 3-5 days at a dose of 3000 IU with a total course of 7 to 15 injections.

3. To increase the bioavailability of medicinal and diagnostic drugs (antibiotics, chemotherapy, anesthetics) Long-dose is administered once in 3 days in a dose of 1500 IU. The course should not exceed 10 injections.

Patients with renal insufficiency should not be prescribed more than once a week.

Preparation of the solution

For intramuscular, subcutaneous or intradermal administration, the contents of the vial (ampoule) are dissolved in 1.5-2 ml of 0.25% or 0.5% of the procaine solution.If the procaine is intolerant, the drug is dissolved with 0.9% sodium chloride solution or water for injection.

The prepared solution for parenteral administration is not subject to storage.

Candles

Longitude in the form of candles is recommended for rectal or vaginal application 1 time per day for the night, for the course - 10-20 injections.

Rectal: 1 candle once a day after cleansing of the intestine.

Intravaginal: 1 candle once a day for the night; The suppository is inserted into the vagina in the supine position.

The treatment regimen is adjusted depending on the severity, stage and duration of the disease. It is possible to administer the drug every other day or with interruptions of 2-3 days.

Recommended treatment regimens

In urology

On 1 suppository every other day - 10 introductions, then in 2-3 days - 10 introductions. General course of 20 introductions.

In gynecology

Rectally or intravaginally with 1 suppository in 2 days - 10 administrations, then, if necessary, maintenance therapy is prescribed.

In dermatovenerology

For 1 suppository in 1-2 days - 10-15 introductions.

In surgery

On 1 suppository in 2-3 days - 10 introductions.

In pulmonology and phthisiology

On 1 suppository in 2-4 days - 10-20 vestings.

If necessary, it is recommended that the repeated course of Longidase not earlier,than in three months or long maintenance therapy - 1 candle 1 time in 5-7 days for 3-4 months.

Side effect

• soreness at the injection site;
• hyperemia of the skin at the injection site;
• swelling of tissues at the site of administration;
• allergic reactions.

Contraindications

• malignant neoplasms;
• pregnancy;
• children's age till 12 years (efficiency and safety have not been studied);
• increased individual sensitivity to the drug.

Application in pregnancy and lactation

The drug is contraindicated for use in pregnancy.

special instructions

The drug should not be injected into the area of ​​infection, acute inflammation or tumor.

Drug Interactions

Longitude is compatible with antibiotics, antiviral, antifungal and antihistamine drugs, bronchodilators, cytostatics, glucocorticosteroids.

When combined, increases the bioavailability of drugs, accelerates the onset of analgesia with the administration of local anesthetics.

Analogues of Longidase drug

Structural analogs for the active substance:

• Lidase;
• Lidase (for injection);
• Lidase-M;
• RONIDASE.

Similar medicines:

Other medicines: